Kornimate/medical-research-clean huggingface dataset:
flowtriever all-comer registry for patient safety and hemodynamics

Conditions: PE - Pulmonary Embolism; PE - Pulmonary Thromboembolism

Summary: to evaluate the safety and effectiveness of the flowtriever system for use in the removal of emboli from the pulmonary arteries in the treatment of acute pulmonary embolism (pe). the use of the device will be assessed in a real-world population, with eligibility criteria that closely approximate its use in clinical practice. up to 300 additional patients with anticoagulation treatment as the initial planned primary treatment strategy for intermediate risk pe will also be evaluated (us only).


Eligibility criteria:
inclusion criteria: * clinical signs and symptoms consistent with acute pe * echo, ctpa or pulmonary angiographic evidence of proximal filling defect in at least one main or lobar pulmonary artery * scheduled for pe treatment with the flowtriever system per the investigator's discretion\* * us only: patients enrolled in the conservative therapy sub-study are not required to meet this inclusion criteria but must instead be scheduled for primary anticoagulation therapy as the primary treatment strategy. exclusion criteria: * unable to be anticoagulated with heparin or alternative * diagnosis with a minor pe with a less than 0.9 rv/lv ratio * known sensitivity to radiographic contrast agents that, in the investigator's opinion, cannot be adequately pre-treated\* * imaging evidence or other evidence that suggests, in the investigator's opinion, the subject is not appropriate for mechanical thrombectomy intervention\* * life expectancy \< 30 days, as determined by investigator * current participation in another investigational drug or device treatment study that, in the investigator's opinion, would interfere with participation in this study * us only patients enrolled in the conservative therapy sub-study are not required to meet these exclusion criteria

Keywords: pe pulmonary embolism thromboembolism thrombectomy flowtriever anticoagulation medication
thrombophilic risk factors in preterm and infants treated at ha'emek medical center between the years 1990 to 2010

Conditions: Premature; Thrombosis

Summary: there are several factor that can be related to neonatal thrombotic events. among them hypercoagulability can be the cause of those events. factor v leiden (fvl) and prothrombin mutation are the most common causes of hereditary thrombophilia. the incidence of in the arab population is known to be higher than the incidence in another western populations. the purpose of this study is to review retrospectively the thrombophilic risk factors that were found in a cohort of premature babies and term newborns treated and investigated at the neonatal intensive care unit and at the pediatric hematology unit.

all the demographic and clinical data will be summarized. factors non related to the coagulation system like catheters, severe infections or congenital heart defects will be recorded. also a full workup of prothrombotic risk factors are routinely performed in those infants. the study included basic coagulation analysis, protein c, s and antithrombin iii activity, activated protein c resistance, serum homocystein, lipoprotein (a) and lupus anticoagulant. also the three common genetic factors are analysed including factor f leiden (g1691a), prothrombin mutation (g20210a) and mthfr polymorphism (c677t).

Eligibility criteria:
inclusion criteria: -all newborns (term and premature) diagnosed with neonatal thrombotic events between year 1990 to 2010.

Keywords: newborns
phototherapy versus pregabalin in treatment of refractory ureamic pruritis

Conditions: Refractory Uremic Pruritis

Summary: patients will be randomly assigned into 2 groups: 1. group a: (20 patients) will receive nb uvb phototherapy 3 sessions per week for 2 months. 2. group b: (20 patients) will receive pregabalin oral therapy (50mg after each dialysis session) for 2 months.


Eligibility criteria:
inclusion criteria: 1. age: 20-60 years. 2. end stage renal disease (the last stage(stage 5) of chronic disease which means kidneys are only functioning at 10 to 15 percent of their normal capacity and dialysis or kidney transplant is necessary to stay alive). 3. refractory uremic pruritis. exclusion criteria: 1. other causes of pruritis (dermatological or systemic) e.g. atopic, cholestatic liver disease. 2. photosensitivity. 3. contraindication or allergy to pregabalin. 4. patients on antipruritic drugs e.g. antihistamines, steroids, emollients, opioid agonists.
photodynamic therapy in locally advanced hilar cholangiocarcinoma

Conditions: Treatment Response; Adverse Events; Feasibility

Summary: to determine the safety and efficacy of photodynamic therapy with a novel photosensitizer and a flexible laser probe in locally advanced hilar cholangiocarcinoma.

photodynamic therapy (pdt) is a way of producing tissue necrosis with light after prior administration of a photosensitizing agent. the most important advantages include the possibility of combining pdt with other target therapies and repeat the process as needed with a favorable outcomes. the combination of diverse therapeutic modalities is one of the new strategies to enhance oncologic treatments for pancreatic cancer. in order to overcome the limitations of each treatment modalities and to prevent the development of resistance, the application of pdt combined with target therapies, without increasing the toxicity for the patient, is being widely investigated. pdt has been only extensively studied for the treatment of various superficial skin cancers in the europe but not available in the united states and japan due to the overlapping treatment fields. in korea, the use of first-generation and second-generation photosensitizers are part of the study of gastroenterology, dermatology, otolaryngology, and gynecology. recently, although the investigators have introduced pdt using novel photosensitizers has not yet been used for the treatment of pancreatic cancers. this study aim to determine the safety and efficacy of photodynamic therapy with a novel photosensitizer in locally advanced hilar cholangiocarcinoma.

Eligibility criteria:
inclusion criteria: 1. locally advanced cholangiocarcinoma confirmed to be unsuitable for surgical resection 2. exhibiting disease progression without distant metastasis after conventional chemoradiation therapy at multidisciplinary team discussion in asan medical center 3. pathologically proven cholangiocarcinoma 4. have a negative pregnancy test if appropriate 5. ecog(eastern cooperative oncology group) score 0-2 6. patients to give informed consent and age more than \>19 years exclusion criteria: 1. age less than 18 years 2. previous history of pdt 3. uncorrectable coagulopathy 4. refuse to participate 5. pregnancy 6. recent participation in another clinical research trial within 30 days 7. presence of porphyria or hypersensitivity to photosensitizer 8. creatinine clearance \< 45ml
early mobilization of older adults in the cardiovascular intensive care unit

Conditions: Physical Activity; Older Adults; Cardiovascular Diseases

Summary: an early mobilization (em) program will be implemented in the cardiovascular intensive care unit at the jewish general hospital (jgh), an academic tertiary hospital in montreal, quebec. the investigators will perform a prospective, pre/post-em intervention study in adults aged ≥60 years old admitted to the cardiovascular intensive care unit (cicu) at the jgh. during a 3-month period, the investigators will prospectively enrol patients to the pre-intervention cohort. the em intervention will then be implemented. during a 12-month period, the investigators will prospectively enrol patients to the intervention cohort. 1 and 12 months following hospital discharge, patients in the pre-intervention and post-intervention cohorts will be contacted by phone by a member of the research team to assess for functional status and quality of life measures. the primary effectiveness outcome will be the mean improvement in level of function (lof) during cicu admission and at 1 and 12 months. covariates predicting improvement in lof ("responsiveness") and ones which do not ("non-responsiveness") will be assessed. the recovery of physical function at 1 month and 6 months as measured by the sf-36 physical component summary score will be assessed. the sf-36 scores of the highest scoring tertile of lof on hospital discharge will be compared with the lowest scoring tertile. hospital readmission at 30 days and discharge home vs. healthcare facility will also be compared. for safety, the composite and individual components of the number of falls, injuries, and dislodgements over the total number of attempted mobility activities will be recorded. the results from the intervention cohort will be compared to the pre-intervention cohort for all results.


Eligibility criteria:
inclusion criteria: * participating in early mobilization program * age 60 years old or older exclusion criteria: * cicu stays less than 24 hours * patients with prehospital lof 0 (immobile), lof 1 (bedbound) or 2 (can sit in chair only). * cardiac surgery patients will also be excluded.
stellarex vascular e-registry

Conditions: Peripheral Arterial Disease

Summary: prospective, international, multi-center, single arm, observational study to continue to assess the treatment by the stellarex™ otw drug-coated angioplasty balloon in superficial femoral and/or popliteal arteries according to the instructions for use in a broad, real-world, claudicant or ischemic rest pain patients population per the institution's standard practice.


Eligibility criteria:
inclusion criteria: * patients intended to be treated with stellarex for de-novo or restenotic lesions of the femoro-popliteal arteries * rutherford clinical category (rcc) 2-3 or 4 indicated for a percutaneous transluminal angioplasty according to local applicable guidelines * age ≥18 years old * life expectancy \> 1 year * is able and willing to provide written informed consent prior to enrollment in the study (as applicable) * is able and willing to come on site or to be contacted by phone for the follow-up exclusion criteria: * patients with any medical condition that would make him/her inappropriate for treatment with stellarex as per instructions for use (ifu) or investigator's opinion * patient already enrolled in other investigational (interventional) studies that would interfere with study endpoints * patients that in the judgment of the investigator would need treatment below the knee before and/or during the index procedure.
short course radiation therapy in palliative treatment of head and neck cancer

Conditions: Head and Neck Cancer; Radiotherapy; Palliative Care

Summary: aim of the study is to assess efficacy of a short course radiation treatment in patients with symptomatic head and neck (h\&n) malignant lesions

standard treatment for h\&n lesions (3000 cgy in 10 daily fractions of 300 cgy each) is compared with experimental treatment (2000 cgy in 4 fractions of 500 cgy twice a day) to demonstrate non-inferiority of this scheme

Eligibility criteria:
inclusion criteria: * symptomatic h\&n malignant lesions (primary solid tumors or metastases from solid tumor) * age\>18 years * eastern cooperative oncology group (ecog) performance status 0-3 * no changes in supportive care in the week before radiotherapy exclusion criteria: * pregnancy * previous irradiation of the same region

Keywords: short course radiotherapy symptomatic head and neck lesions
bowditch revisited: defining the optimum heart rate range in chronic heart failure

Conditions: Chronic Heart Failure

Summary: the investigators are examining the relationship between heart rate and heart contraction in patients with heart failure and pacemakers, aiming to improve quality of life.

heart rate lowering is a cornerstone of the management of chronic heart failure (chf) and the degree of lowering is closely related to improvements in longevity, hospitalisation rate and heart function. the investigators have shown that increasing heart rates using pacemakers does not increase exercise capacity in chf patients. this might be because the optimal heart rate range for contraction is narrower for patients with chf. at higher heart rates, heart contraction might be less strong. the investigators now want to examine the relationship between heart rate and heart contraction in patients with heart failure and pacemakers. tailored pacemaker heart rate setting's, individually optimised for heart contractility as assessed by cardiac ultrasound, will be investigated to examine the effects on exercise tolerance .

Eligibility criteria:
inclusion criteria: * stable chf * cardiac resynchronisation therapy (crt) device for \>3 months, * able to walk on treadmill exclusion criteria: * unable to walk on treadmill, * unstable angina pectoris * uncontrolled heart rate * prescribed calcium channel blocker * significant aortic stenosis * significant airways disease
effect of non-dissection of the inferior rectus sheath on intraoperative blood loss

Conditions: Acute Blood Loss Anemia; Postoperative Pain; Pregnancy

Summary: the purpose of this study is to evaluate the effect of non-dissecting the inferior rectus sheath during primary cesarean delivery on post-operative hemoglobin and post-operative pain control as measured by vas score and opioid anesthesia use in the first 72 hours post-op.


Eligibility criteria:
inclusion criteria: * - patients must be 18 years or older as well as willing and able to provide informed consent * patients undergoing a scheduled or non-scheduled, non-urgent or non-scheduled urgent (delivery within 30 minutes of decision for surgical delivery) cesarean delivery between \>35 weeks gestational age, * patients who are expected to receive a pfannenstiel incision * patients with viable singleton intra-uterine pregnancy * patients with fetus in cephalic presentation exclusion criteria: * - patients younger than 18 years, * patients unable or unwilling to provide informed consent, * patients who are illiterate, * patients who are non-english speaking or reading, * patients who are medical or nursing students at a school affiliated with university hospital * multi-fetal gestations (\>1 intrauterine pregnancy), * patients with a bmi \>50 kg/m\^2 * patients with a suspected placenta accreta or placenta previa * patients with 2 prior cesarean deliveries * patient undergoing emergent cesarean delivery (delivery within 10 minutes of decision for surgical delivery) * patients who will require a vertical skin incision, maylard or cherney incisions * patients with a history of significant pelvic adhesive disease, as determined by prior operative reports * patients with fetus in non-cephalic presentation * patients with pre-gestational or gestational diabetes mellitus * patients with estimated fetal weight \>5000 grams * patients with estimated fetal weight \<10% for gestational age * patients with who require general anesthetic * patients who are on chronic pain medication * patients with a history of drug abuse
impact of correction of vitamin d deficiency in oxidative stress in patients with prediabetes (vicox)

Conditions: Vitamin D Deficiency; Glucose Intolerance; Oxidative Stress; Insulin Resistance

Summary: the investigators aim to determine the effect of the correction of vitamin d in vitamin d deficient patients (\<15ng/ml) in oxidative stress and insulin resistance in patients with impaired glucose tolerance. vitamin d deficiency has been associated with chronic low-grade inflammation, diabetes mellitus type 2, cardiovascular risk and increased prevalence of coronary heart disease, cerebrovascular disease and myocardial infarction.


Eligibility criteria:
inclusion criteria: * women, 18 to 70 years, glucose intolerance (post-2 hour 75-grams glucose load \> or equal 140 mg/dl), 25-hydroxy vitamin d concentration \< or equal 15 ng/ml exclusion criteria: * diabetes, systemic inflammatory disorders, treatment with statins, metformin or fibrates, renal insufficiency, intestinal malabsorption
evaluation of consumption of sevoflurane in chronic obstructive pulmonary disease patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: all the patients undergoing general anesthesia and the patients who are having chronic obstructive pulmonary disease will be considered for this study. the volume consumption of sevoflurane will be studied in accordance with age, sex, duration , type of surgery, site of surgery and bmi.the volume consumption of sevoflurane is compared with chronic obstructive pulmonary disease and normal patients .

chronic obstructive pulmonary disease is known to escalate the consumption of inhalation agents in general anesthesia. hence the data to collect the official record

Eligibility criteria:
inclusion criteria: * both sex all age group patient willing to give consent copd patient exclusion criteria: * not willing to give consent cancerous lung lung lobectomy
standard palliative care versus standard palliative care plus polychemotherapy in metastasized malignant melanoma

Conditions: Metastatic Melanoma

Summary: the purpose of this multicenter study is to examine whether the proposed randomized treatment regime results in a significantly longer survival time and higher quality of life than any additionally applied multiple chemotherapy according to the cvd- scheme. so far neither established treatment regimes nor reliable data exist for the second-line chemotherapy of metastatic malignant melanoma. patients are therefore mostly treated with single or multiple chemotherapeutics or/and immunomodulatory therapeutics. these regimes however imply often not only a higher toxicity but show rarely a response rate higher than 10%.


Eligibility criteria:
inclusion criteria: * histological diagnosis of metastatic melanoma (stage iv) * progressive disease after first-line chemotherapy or immuno-chemotherapy * karnofsky-index \> 60% * informed consent exclusion criteria: * uvea melanoma * another primary malignancy except basal cell carcinoma or cervical carcinoma in situ * severe and/or uncontrolled medical disease (diabetes mellitus, cardiac insufficiency)

Keywords: malignant melanoma chemotherapy metastasis standard palliative care best supportive care
clinical evaluation of the efficacy of fractional radiofrequency for the treatment and reduction of stretch marks

Conditions: Stretch Mark

Summary: this is a prospective, single centre, evaluator-blind study of the performance of fractional radiofrequency (rf) for the treatment and revision of stretch marks. the study will evaluate the progress of 15 subjects requesting treatment of stretch marks. the study will involve four treatments on both sides of the face with 4 week intervals between each treatment. subjects will be followed at 12 and 16 weeks after their last treatment. analysis will be performed on all subjects who receive at least one treatment.


Eligibility criteria:
inclusion criteria: 1. healthy, male or female subjects, 18-60 years of age who are seeking treatment for their stretch marks 2. fitzpatrick skin type i-iv 3. able to read, understand and voluntarily provide written informed consent. 4. able and willing to comply with the treatment/follow-up schedule and requirements. exclusion criteria: 1. pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body (e.g. cochlear implant). 2. subjects with any implantable metal device in the treatment area 3. permanent implant in the treated area, such as metal plates and screws (excluding dental implants), or an injected chemical substance. 4. current or history of any kind of cancer, or dysplastic nevi in the treated area. 5. severe concurrent conditions, such as cardiac disorders. 6. impaired immune system due to immunosuppressive diseases, such as aids and hiv, or use of immunosuppressive medications. 7. history of diseases stimulated by heat, such as recurrent herpes simplex in the treatment area; may be enrolled only following a prophylactic regime. 8. poorly controlled endocrine disorders, such as diabetes. 9. any active condition in the treatment area, such as sores, psoriasis, eczema, and rash. 10. history of skin disorders, such as keloids, abnormal wound healing, as well as very dry and fragile skin. 11. history of bleeding coagulopathies, or use of anticoagulants. 12. use of isotretinoin (accutane®) or other systemic retinoids limited up to 10mg/day or as per investigators discretion. 13. treating over tattoo or permanent makeup. 14. excessively tanned skin from sun, tanning beds or tanning creams within the last two weeks.
the role of sleep in the treatment of cannabis use disorders

Conditions: Drug Addiction

Summary: the number of people seeking treatment for marijuana-related problems is on the rise, yet there is no currently accepted medication proven to help them quit. frequent marijuana users have reported that they have trouble sleeping when they try to quit, and that the loss of sleep can lead to relapse. this research is designed to measure the severity of sleep problems in people as they are trying to quit heavy use of marijuana, and to investigate whether extended-release zolpidem (ambien cr®) can improve quit rates among people trying to stop using marijuana.


Eligibility criteria:
inclusion criteria: 1. age 18-55 years. 2. recent problematic use of cannabis 3. cannabis use impacts sleep exclusion criteria: 1. dependent on drugs other than cannabis or nicotine, or current axis i psychiatric disorder 2. moderate sleep apnea or periodic limb movement disorder 3. pregnant, breast feeding, or planning to become pregnant within the next 3 months 4. current condition associated with severe cognitive/social impairment 5. allergy to any ingredient in extended-release zolpidem or prior adverse reaction to zolpidem 6. current use of drugs that affect metabolism via cytochrome p450 or current illness resulting in severe hepatic impairment 7. current use of hypnotic medications

Keywords: marijuana cannabis treatment insomnia relapse
hepatocellular carcinoma recurrence and anesthesia

Conditions: Hepatocellular Carcinoma

Summary: the investigators will verify the prognosis of hepatocellular carcinoma (hcc) according to the main anesthetic agents used for the general anesthesia.


Eligibility criteria:
inclusion criteria: * patients undergoing surgery due to the hcc. exclusion criteria: * patients undergoing re-operation due to the hcc. * patients presenting distant metastasis. * patients undergoing liver transplantation surgery.
exercise training in chagas cardiomyopathy

Conditions: Chagas Disease; Cardiomyopathy; Exercise Training

Summary: the benefits of exercise training in heart failure are well established. its effects, however, have not been evaluated in chagas cardiomyopathy (chc). the investigators hypothesis is that the exercise training may improve functional capacity, quality of life (qol), and reduce brain natriuretic peptide (bnp) levels in patients with chc.


Eligibility criteria:
inclusion criteria: * chronic chagas dilated cardiomyopathy, defined by the echocardiography finding of a dilated left ventricle with moderate or severe impaired left ventricular systolic function (left ventricular ejection fraction ≤ 45%). * to be clinically stable for at least 3 months * to have sinus rhythm * to be under standard medical therapy use at the time. exclusion criteria: * inability to attend regular exercise training * the presence of a pacemaker, associated cardiac or systemic diseases * practitioners of regular physical activity

Keywords: chagas disease chagas cardiomyopathy exercise movement techniques